Nuwellis, Inc. Common Stock (NUWE)

Price$0.70

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-78.91%

Price vs S&P 500 (4W)-32.66%

VGM Score18.20

Market Capitalization$2.07M

All Metrics

Book Value / Share (Quarterly)$1.01

P/TBV (Annual)0.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.07%

Cash Flow / Share (Quarterly)$-4.40

Price vs S&P 500 (YTD)-66.47%

Gross Margin (TTM)65.47%

Net Profit Margin (TTM)-217.22%

EPS (TTM)$-64.11

10-Day Avg Trading Volume0.18M

EPS Excl Extra (TTM)$-64.11

Revenue Growth (5Y)2.14%

EPS (Annual)$-25.39

ROI (Annual)-666.20%

Gross Margin (Annual)61.96%

Net Profit Margin (5Y Avg)-196.92%

Cash / Share (Quarterly)$0.79

Revenue Growth QoQ (YoY)26.21%

ROA (Last FY)-286.38%

Revenue Growth TTM (YoY)-0.20%

EBITD / Share (TTM)$-10.52

ROE (5Y Avg)-331.89%

Operating Margin (TTM)-143.85%

Cash Flow / Share (Annual)$-6.46

P/B Ratio0.78x

P/B Ratio (Quarterly)1.04x

Net Income / Employee (Annual)$-461,100

EV / Revenue (TTM)-0.00x

Net Interest Coverage (TTM)-0.66x

ROA (TTM)-251.77%

EPS Growth QoQ (YoY)-99.24%

EPS Incl Extra (Annual)$-25.39

Current Ratio (Annual)1.71x

Quick Ratio (Quarterly)1.09x

3-Month Avg Trading Volume1.47M

52-Week Price Return-97.99%

Revenue / Employee (TTM)$230,800

Tangible BV / Share (Quarterly)$0.97

P/S Ratio (Annual)0.25x

Asset Turnover (Annual)1.35x

52-Week High$40.07

Operating Margin (5Y Avg)-179.25%

EPS Excl Extra (Annual)$-25.39

CapEx CAGR (5Y)-21.40%

Tangible BV CAGR (5Y)-5.32%

26-Week Price Return-62.98%

Quick Ratio (Annual)1.08x

13-Week Price Return-51.64%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.56x

Enterprise Value$-8,900

Revenue / Share Growth (5Y)-49.70%

Asset Turnover (TTM)1.16x

Book Value / Share Growth (5Y)-68.99%

Revenue / Employee (Annual)$217,600

Inventory Turnover (Annual)1.73x

Pretax Margin (Annual)-211.80%

Cash / Share (Annual)$0.64

3-Month Return Std Dev77.61%

Gross Margin (5Y Avg)59.11%

Net Income / Employee (TTM)$-501,300

ROE (Last FY)-666.20%

Net Interest Coverage (Annual)-0.19x

EPS Basic Excl Extra (Annual)$-25.39

Receivables Turnover (TTM)5.66x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-64.11

Receivables Turnover (Annual)5.14x

ROI (TTM)-211.49%

P/S Ratio (TTM)0.24x

Pretax Margin (5Y Avg)-196.85%

Revenue / Share (Annual)$11.98

Tangible BV / Share (Annual)$23.04

Price vs S&P 500 (52W)-126.19%

Year-to-Date Return-55.53%

5-Day Price Return-26.31%

EPS Normalized (Annual)$-25.39

ROA (5Y Avg)-145.92%

Net Profit Margin (Annual)-211.86%

Month-to-Date Return-31.53%

Cash Flow / Share (TTM)$-13.85

EBITD / Share (Annual)$-15.80

Operating Margin (Annual)-134.29%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-331.80%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-64.11

P/TBV (Quarterly)1.08x

P/B Ratio (Annual)1.10x

Inventory Turnover (TTM)1.72x

Pretax Margin (TTM)-217.17%

Book Value / Share (Annual)$1.56

Price vs S&P 500 (13W)-61.39%

Beta0.24x

Revenue / Share (TTM)$4.23

ROE (TTM)-211.49%

52-Week Low$0.73

gGradeD

mGradeF

vgmGradeF

Show chart for

Earnings Surprise History

Q1 26-2.09est. -1.02

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

2.17

Industry Peers — Electromedical Equipment(31)

Symbol	Value Score	Growth Score	Momentum Score	Price
NUWENuwellis, Inc. Common Stock	—	D	F	$0.70
MDTMedtronic plc	B	D	D	$73.98
MASIMasimo Corporation	D	D	B	$178.59
LIVNLivaNova PLC Ordinary Shares	C	C	B	$73.81
ITGRInteger Holdings Corporation	B	C	C	$90.16
TMDXTransMedics Group, Inc. Common Stock	C	B	F	$67.53
AXGNAxogen, Inc. Common Stock	F	B	B	$38.72
BLFSBioLife Solutions Inc.	F	B	B	$26.63
CNMDCONMED Corporation	A	C	D	$34.65
INMDInMode Ltd. Ordinary Shares	A	D	C	$13.59
CBLLCeriBell, Inc. Common Stock	D	A	C	$17.61

About

Nuwellis Inc manufactures ultrafiltration devices for treating fluid overload in patients unresponsive to conventional medical management. The company's primary products, the Aquadex FlexFlow and Aquadex SmartFlow systems, remove excess fluid in conditions such as congestive heart failure. Nuwellis operates a single business segment focused on fluid overload treatment.